𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer

✍ Scribed by Ava Kwong; L. P. Wong; H. N. Wong; F. B. F. Law; E. K. O. Ng; Y. H. Tang; W. K. Chan; L. S. Ho; K. H. Kwan; M. Poon; T. T. Wong; F. C. S. Leung; S. W. W. Chan; M. W. L. Ying; E. S. K. Ma; J. M. Ford


Publisher
Springer US
Year
2009
Tongue
English
Weight
164 KB
Volume
117
Category
Article
ISSN
0167-6806

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Recurrent BRCA1 and BRCA2 germline mutat
✍ Ui-Soon Khoo; Kelvin Y.K. Chan; Annie N.Y. Cheung; W.C. Xue; D.H. Shen; K.Y. Fun πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 156 KB πŸ‘ 2 views

Previous mutational analysis for BRCA gene mutations in sporadic ovarian cancer occurring in Chinese patients in Hong Kong identified six germline BRCA1 mutations and one germline BRCA2 mutation, six of which were novel (Khoo et al., 2000). Knowledge of BRCA gene mutations in the Chinese population

Founder BRCA1 mutations and two novel ge
✍ Marco van der Looij; Barbara Wysocka; Izabela Brozek; Jacek Jassem; Janusz Limon πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 30 KB πŸ‘ 3 views

Germline mutations in the BRCA1 and BRCA2 genes account for the majority of high-risk breast/ovarian cancer families, depending on the population studied. Previously, BRCA1 mutations were described in women from Western Poland. To further characterize the spectrum of BRCA1 mutations and the impact o

Prevalence of founder BRCA1 and BRCA2 mu
✍ Marco Van der Looij; Csilla Szabo; Istvan Besznyak; Gyorgy Liszka; Bela Csokay; πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 French βš– 55 KB πŸ‘ 2 views

We have investigated the impact of BRACA1 and BRACA2 mutations that were frequently identified among Hungarian high-risk breast-ovarian cancer families (Ramus et al., 1997b, AJHG), on the development of breast and ovarian cancer in the general Hungarian population. The prevalence of 3 BRCA1 mutation